PGEN
Precigen, Inc.
Biotechnology · Healthcare · United States
6.94
close · 2026-10-30
value
66
cheaper than peers66
quality
34
stronger fundamentals34
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | 2.0% | 90 |
| cash flow yield, 2 years ago | -2.8% | 74 |
| cash flow yield, 1 year ago | -3.1% | 74 |
| earnings yield, 2 years ago | -5.6% | 74 |
| cash flow yield, 3 years ago | -2.8% | 71 |
| earnings yield, 1 year ago | -6.8% | 67 |
| cash flow yield, latest year | -3.6% | 67 |
| earnings yield, latest year | -19.7% | 41 |
| price to sales | 78.64× | 15 |
| price to book | 56.89× | 4 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 1633.9% | 94 |
| operating margin | -25.8% | 69 |
| debt to equity | 485.5% | 5 |
| return on equity | -1145.4% | 1 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$90.1M |
| employees | 160 |
| first trade | 2013-08-08 |
| next earnings | 2026-11-04 |
| fundamentals updated | 2026-08-05 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.37 | -0.47 | -0.39 | 0.14 |
| free cash flow | -$89.8M | -$76.8M | -$68.5M | -$70.0M |
| net income | -$250.6M | -$126.2M | -$95.9M | $28.3M |
| revenue | $9.7M | $3.9M | $6.2M | $26.9M |
| unusual items | -$143.4M | -$40.3M | -$10.8M | -$1.1M |